Skip to content

Fact Sheet: Ncyte® NHP-C vCardiomyocytes

Get information on Ncardia’s Ncyte® NHP-C vCardiomyocytes, high-purity non-human primate CMs designed for translational cardiac research, electrophysiology, and preclinical safety assessment.
DOWNLOAD NOW
Screenshot 2026-03-11 at 10.15.39 AM

Discover Ncyte® NHP-C vCardiomyocytes

Cynomolgus non-human primate iPSC-derived ventricular-like cardiomyocytes provide a physiologically relevant in vitro system for translational cardiac research, enabling cross-species comparison between preclinical models and human biology. This platform supports mechanistic studies, cardiotoxicity screening, and drug development programs with improved translational confidence. 

Ncyte® NHP-C vCardiomyocytes are functional, electrophysiologically active cardiomyocytes that form beating clusters within 72 hours and are compatible with assays such as MEA electrophysiology, imaging, impedance, contractility, and metabolic profiling. Their strong pharmacological responsiveness makes them suitable for cardiac safety testing and compound evaluation across discovery and preclinical research. 

 




ABOUT US
Predict future safety and efficacy more efficiently
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.

Download the fact sheet by filling out the form below: